Navigation Links
Sangamo BioSciences Announces Results From Diabetic Neuropathy Clinical Trial SB-509-601
Date:11/10/2008

The passcode for the call is 2585543. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on November 10, 2008 to midnight, Monday November 17, 2008. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820, respectively. The conference ID number for the replay is 2585543.

About SB-509

SB-509 is an injectable formulation of a plasmid encoding a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)) designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF- A). VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties. In preclinical animal efficacy studies in a diabetic rat model (Diabetes, June 1, 2006; 55(6): 1847-1854), SB-509 has proven effective in protecting motor and sensory nerve function from disease- induced nerve damage.

Phase 2 Study of SB-509 for Mild to Moderate DN (SB-509-601)

The study is a double-blind, placebo-controlled, repeat-dosing multi- center study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetics with mild to moderate diabetic peripheral sensory motor neuropathy in the legs.

110 subjects were enrolled into the trial. Subjects were randomized to one of two groups. The larger group was treated by intramuscular injection of 60 mg of SB-509 (30 mg of SB-509 per leg) into the lower limb every two months. The remaining group received an equal volume of placebo on the same schedule. Each subject received a total of three treatments (Day 0, 60 and 120). Subjects received injections in a distribution pattern that targets the major peripheral nerves in the legs and feet.

The symptoms of diabetic peripheral neuropathy and any changes that occur during the trial were evaluated based on neurological ex
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2008 Financial Results
2. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
3. Sangamo BioSciences Announces Third Quarter Conference Call and Webcast
4. Sangamo BioSciences to Present at Two Upcoming Investor Conferences
5. Sangamo BioSciences to Present at the UBS Global Life Sciences Conference
6. Sangamo BioSciences to Present at the Canaccord Adams Global Growth Conference
7. Sangamo BioSciences to Present at the BMO Capital Markets Focus on Healthcare Conference
8. Sangamo BioSciences Reports Second Quarter 2008 Financial Results
9. Sangamo BioSciences Announces Second Quarter Conference Call and Webcast
10. Sangamo BioSciences and Sigma-Aldrich Announce Research and License Agreement With Roche for the Use of ZFN Technology for Generation of Transgenic Animals
11. Dow AgroSciences Announces Early Exercise of Option for Commercial License With Sangamo BioSciences for Plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... that it has been granted a patent by ... its unique delivery system for delivering its "original" ... for the treatment of diseases with an inflammatory ...
(Date:9/17/2014)... Cary, N.C. (PRWEB) September 17, 2014 ... solutions that advances science and healthcare, has renewed its ... term. , As part of the agreement, Personify will ... with a sustained emphasis on recruitment analytics, including time-to-fill, ... decision to renew our agreement with Personify was based ...
(Date:9/17/2014)... , September 17, 2014 ... of action from a truly novel class ... MGB Biopharma, a biopharmaceutical company developing ... today that it has secured £4.0m ($6.4m) ... antibacterial, MGB-BP-3, against a range of Gram-positive ...
(Date:9/17/2014)... Wilmington, DE (PRWEB) September 17, 2014 ... profit organization committed to lowering the barriers to ... has announced the appointment of Carmen Nitsche as ... organization looks to expand its global reach. , ... she was Vice President, Corporate Development. At Accelrys, ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... SAN DIEGO, July 28, 2011 Gen-Probe Incorporated (NASDAQ: ... quarter of 2011, with total revenues of $135.9 million and ... "Gen-Probe posted record sales of APTIMA women,s health products in ... blood screening revenue to decline compared to strong sales a ...
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... the second quarter of 2011, the Company reported net income of ... of $5.2 million, or $0.09 loss per share, for the same ... the Company reported net income of $4.9 million, or $0.09 per ...
... ITMN ) today announced that it will release its ... A live conference call and webcast will be hosted by ... discuss business highlights and financial results for the second quarter ... the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ...
Cached Biology Technology:Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14Neurocrine Biosciences Reports Second Quarter 2011 Results 2Neurocrine Biosciences Reports Second Quarter 2011 Results 3Neurocrine Biosciences Reports Second Quarter 2011 Results 4Neurocrine Biosciences Reports Second Quarter 2011 Results 5Neurocrine Biosciences Reports Second Quarter 2011 Results 6Neurocrine Biosciences Reports Second Quarter 2011 Results 7InterMune to Release Second Quarter Financial Results on August 4 2
(Date:9/16/2014)... severe maternal morbidity amongst women in Australia is ... study published today (17 September) in BJOG: ... , Australians generally enjoy high standards of living; ... exist, in particular between indigenous and non indigenous ... the independent impact of socioeconomic position on severe ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Biobanks are repositories for tissue samples, usually in ... from surgical procedures. These samples are collected and used ... linked to personal health information regarding the sample donor. ... researchers who want to use them face important questions ...
... The Life Sciences Discovery Fund (LSDF) today announced awards ... therapies and key resources for medical researchers and health-care ... the three programs. The programs will be led ... across the state. Dr. David Flum will work with ...
... MADISON, WI, JUNE 28, 2011 -- The ... provides information needed to sustainably manage agroforestry systems. ... increase yields and also reduce financial and environmental ... that allows for site-specific evaluation of nutrient-production imbalances ...
Cached Biology News:Public prefers limited informed consent process for biobanks 2Public prefers limited informed consent process for biobanks 3Life Sciences Discovery Fund helps launch 3 programs to advance health research and development 2Analyzing agroforestry management 2
... MKK6 (phospho S207) ( Abpromise ... Antigen: Synthetic phosphopeptide derived ... site of Serine 207 (V-D-S P ... ID: 5608 ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: